InsidersTradesSigma
申报总数
公司
▲ 买入（3 笔）
▼ 卖出（2 笔）
内部人交易记录
其他已披露买入
3
已披露卖出
2
T+90 胜率
50%
T+90 平均收益
-19.5%
基于 2 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Discover the detailed record of transactions filed by New Enterprise Associates 16, L.P.. Insider active across 7 companies, notably Trevi Therapeutics, Inc.. Aggregated, 8 filings have been recorded. Breakdown: 3 buys · 2 sells. Total volume traded: €6.3m. Activity tracked since 10 December 2021. The latest transaction was disclosed on 2 October 2025 (X). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to New Enterprise Associates 16, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报8 总计
189,195 股@ US$0.01100.0% 占其流量Common StockSEC:0001193125-25-232130:0
554,250 股@ US$3.20100.0% 占其流量Common StockSEC:0000950170-24-139630:0
标准退出：2025年3月23日 (T+90)
2,000,000 股0Common StockSEC:0001209191-23-037333:0
4,294,207 股Common StockSEC:0001209191-22-059440:0
5,931,843 股@ €0.0609100.0% 占其流量Common StockSEC:0001209191-22-032327:0
2,631,578 股@ US$1.90100.0% 占其流量Common StockSEC:0001209191-22-024301:0
标准退出：2022年7月10日 (T+90)
37,570 股@ US$1.321100.0% 占其流量Common StockSEC:0001209191-21-071265:0
1,851,852 股Common StockSEC:0001209191-21-061090:0
标准退出：2022年1月16日 (T+90)
8 条申报中的 8 条
About New Enterprise Associates 16, L.P.
New Enterprise Associates 16, L.P. is a declarant with 8 filings in total. Across the 8 sampled recent filings from 2021-10-19 to 2025-10-06, the stated amounts are EUR 6,296,426 of buys and EUR 43,946 of sells, and the modal transaction nature is Acquisition. The companies mentioned in these filings include Trevi Therapeutics, Inc., NeueHealth, Inc., Marker Therapeutics, Inc., Mirum Pharmaceuticals, Inc., Akouos, Inc. and Genocea Biosciences, INC., and the listed role for NeueHealth, Inc. is Director.
